Diagnostika a léčba plicní arteriální hypertenze

Číslo: 1 / 2011 (Obsah)
Rubrika: Farmakoterapeutické postupy
Obor: Kardiologie
Autoři: MUDr. Hikmet Al-Hiti
Autoři - působiště: Klinika kardiologie IKEM, Centrum pro diagnostiku a léčbu plicní hypertenze, Praha
Klíčová slova: Plicní hypertenze, plicní cévní rezistence, diagnostika, léčba
Citace: 1 Romberg E. Über Sklerose der Lungen Arterie. Dtsch Arch Klin Med 1891;48:197–206. 2 Dresdale DT, Schultz M, Nichrom RJ. Primary pulmonary hypertension. I Clinical and hemodynamic study. Am J Med 1951; 11:686–705. 3 Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 classically diagnose CASE. Circulation 1970;42:1163–84. 4 Moride Y, Abenhaim L, Xu J. Epidemiology of pulmonary hypertension. In: Rubin LJ, Rich S, editors. Primary pulmonary hypertension. New York, NY: Marcel Dekker, 1997:163-78. 5 Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107:216–23. 6 Rich S. Primary pulmonary hypertension: Executive summary from the World Symposium, 1988. 7 Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111–7. 8 Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533–44. 9 Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Eng J Med 2004;351:1655–65. 10 The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2009;30:2493–537. 11 Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France. Results from a National Registry. Am J Respir Crit Care Med 2006;173:1023–30. 12 DAlonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–9. 13 McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–82. 14 Rich S, Kaufmann E, Levy PS. The effect of hight doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81. 15 Groves BM, Badesch DM, Turkevich D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K, ed. Ion flux in pulmonary vascular control. New York, NY: Plenum Press, 1993:317–330. 16 Schrader BJ, Invar S, Kaufmann L, et al. Comparison of the effect of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;29:1060–4. 17 Sitbon O, Hubert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safety identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265–70. 18 Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24:356–65. 19 Sitbon O, Hubert M, Ioos V, et al. Who benefits from long-term calcium-channel blockers therapy in primary pulmonary hypertension. Am J Respir Crit Care Med 2003;167:A440. 20 Franak H, Mlczoch, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-included pulmonary hypertension. Chest 1997;112:714–21. 21 Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vaso-dilatator treatment. J Am Coll Cardiol 1998;32:297–304. 22 Hosenpud J D, Bennett LE, et al. The registry of the International Society for Heart and Lung Transplantation: Seventeenth official report 2000. J Heart and Lung Transplant 2000;11:909–31. 23 Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302. 24 Higenbottam T. Treatment of pulmonary hypertension by inhaled delivery. The Parthenon Publishing Group, 1999:9–17. 25 Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease. A randomized, controlled trial. Ann Intern Med 2000;132:425–34. 26 McLaunghlin VV, Gaine SP, Barts RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293–9. 27 Simonneau G, Barts RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-contolled trial. Am J Respir Crit Care Med 2002;165:800–4. 28 Okano Y, Yoshioka T, Schimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365. 29 Galie N, Manes A, Branzi A. The new clinical trials on pharmaco-logical treatment in pulmonary arterial hypertension. Eur Respir J 2002;20:1037–49. 30 Saji T, Ozawa Y, Ishikita T, et al. Short term hemodynamic effect of new oral PGI 2 analogue, beraporost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996;78:244–7. 31 Nagaya N, Uematsu M, Okano Y, et al. Effects of beraprost sodium, an oral prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188–92. 32 Galie N, Hubert M, Vachiery JL, et al. Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496–502. 33 Barts RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119–25. 34 Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30:61–8. 35 Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000; 35:176–82. 36 Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322–9. 37 Yanagisawa M. The endotelin system. A new target for therapeutic intervention. Circulation 1994;89:1320–2. 38 Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:869–903 . 39 Rubin LJ, Galie N, Badesch BD, et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2004;169:A210 (Abst). 40 Prasat S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342. 41 Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long--term hemodynamic and clinical effects of sildenafil in patient with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207–13. 42 Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patient with pulmonary arterial hypertension. Circulation 2003;108:2006–69. 43 Sastry BKS, Narasimhan C, Reddy NK, et al. Clinical effcacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149–53. 44 Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–903. 45 Nagaya N. Short-term oral administration of L-arginin improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Critl Care Med 2001; 163:887–91. 46 Hubert M, Barst R, Robbins I, et al. Safety and efficacy of bosentan combined with epoprostenol in patiens with severe pulmonary arterial hypertension (Abstract). Am J Respir Crit Care Med 2003;167:A441. 47 Ghofrani HA, Rose F, Schermuly RT, et al. Oral sidenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158–64.

Souhrn

Plicní hypertenze je definována jako abnormální vzestup krevního tlaku v plicnici. Může se vyskytovat při vlastním postižení plicních cév (plicní arteriální hypertenze) či sekundárně (v důsledku chronického srdečního selhání, respiračního onemocnění aj.). Plicní arteriální hypertenze je způsobena zvýšením plicní cévní rezistence (prekapilární forma plicní hypertenze) se zvýšením tlaku v plicnici, zvýšením plicní cévní rezistence a normálním tlakem v levé síni nebo v zaklínění. Průměrný věk nemocných v době stanovení diagnózy je okolo 50 let, s častějším výskytem u žen. Neléčená plicní arteriální hypertenze je smrtelným onemocněním. „

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky